4//SEC Filing
SCHIFF ANDREW N 4
Accession 0001209191-22-054675
CIK 0001557746other
Filed
Oct 25, 8:00 PM ET
Accepted
Oct 26, 7:09 PM ET
Size
11.4 KB
Accession
0001209191-22-054675
Insider Transaction Report
Form 4
SCHIFF ANDREW N
Director
Transactions
- Sale
Common Stock
2022-10-26$17.00/sh−14,540$247,253→ 488,381 total(indirect: By Aisling Capital IV LP) - Sale
Common Stock
2022-10-25$17.02/sh−12,018$204,516→ 502,921 total(indirect: By Aisling Capital IV LP) - Sale
Common Stock
2022-10-24$17.01/sh−14,616$248,586→ 514,939 total(indirect: By Aisling Capital IV LP)
Holdings
- 0
Common Stock
Footnotes (5)
- [F1]These sales were effected pursuant to a Rule 10b5-1 trading plan adopted by the Aisling Capital IV, LP on August 23, 2022.
- [F2]The price reported is a weighted average sales price. The shares were sold in multiple transactions at prices ranging from $17.00 to $17.085, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
- [F3]The reportable securities are owned directly by Aisling Capital IV, LP ("Aisling"), and held indirectly by Aisling Capital Partners IV, LP ("Aisling GP"), as general partner of Aisling, Aisling Capital Partners IV LLC ("Aisling Partners"), as general partner of Aisling GP, and each of the individual managing members of Aisling Partners. The individual managing members (collectively, the "Managers") of Aisling Partners are Dr. Andrew Schiff and Steve Elms. Aisling GP, Aisling Partners, and the Managers share voting and dispositive power over the shares directly held by Aisling. Dr. Schiff disclaims beneficial ownership of these securities and this report is not an admission that he is the beneficial owner of such securities for purposes of Section 16 or for any other purpose, except to the extent of his pecuniary interest therein.
- [F4]The price reported is a weighted average sales price. The shares were sold in multiple transactions at prices ranging from $17.00 to $17.23, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
- [F5]The price reported is a weighted average sales price. The shares were sold in multiple transactions at prices ranging from $17.00 to $17.10, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
Documents
Issuer
Aclaris Therapeutics, Inc.
CIK 0001557746
Entity typeother
Related Parties
1- filerCIK 0001172252
Filing Metadata
- Form type
- 4
- Filed
- Oct 25, 8:00 PM ET
- Accepted
- Oct 26, 7:09 PM ET
- Size
- 11.4 KB